Loading........ 23 views Description: Harry P. Erba, MD, PhD of the University of Alabama at Birmingham School of Medicine, presents a press brief on A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy ... Oncology Tube, 1 hour ago
Nivolumab With Chemotherapy Benefits Acute Myeloid Leukemia (AML) Patients - MedIndia, 2 days ago
Precision AML Trial Adds Pharma Candidates To The Mix - Seeking Alpha, 2 days ago
Daiichi Sankyo presents preliminary safety & efficacy data from phase 1 study of DS-3032 in AML &MDS at ASH meeting
Daiichi Sankyo Company, Limited announced preliminary safety and efficacy data from a phase 1 study of DS-3032, an investigational oral selective MDM2 inhibitor, suggesting that DS-3032 may be a promising treatment for haematological malignancies ...PharmaBiz, 18 hours ago BRIEF-Daiichi Sankyo presents Phase 1 Data for MDM2 Inhibitor DS-3032 in AML, MDS Reuters UK, 2 days ago Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology Bio-Medicine, 2 days ago U.S. FDA Grants Fast Track Designation for HER2-Targeting Antibody Drug Conjugate DS-8201 for HER2-Positive Metastatic Breast Cancer Drugs.com, 13 hours ago
ISLAMABAD: Chief of Awami Muslim League (AML) Sheikh Rashid has said those requesting for constitution of commission in Panama leaks case should know it well that nothing would come out of commission. Those making request for constitution of ...The Nation Pakistan, 15 hours ago Rashid accuses PM of receiving $300 million in motorway kickbacks The Express Tribune, 19 hours ago Nawaz Sharif's doom is nearing close: Sheikh Rashid Online News Pakistan, 1 day ago People believe flats belong to Sharif family: Sheikh Rashid SAMAA TV, 1 day ago
Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Yale Cancer Center team has evaluated the use of hypomethylating agents in patients suffering from Acute Myeloid Leukemia (AML) who were resistant to treatment withInfrosoft, 1 day ago Decitabine an option for select AML, MDS patients MedWire News, 2 days ago
Pfizer Inc. announced new data from a randomized phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly increased overall survival (OS) when ...PharmaBiz, 2 days ago Pfizer's Glasdegib improves OS in AML and MDS patients in phase 2 trial Pharmaceutical Business Review, 2 days ago Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Drugs.com, 13 hours ago Pfizer (PFE) Presents Favorable Data on Leukemia Candidate Yahoo! Canada, 2 days ago
BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH..
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase 2a correlative data, as well as ...ADVFN India, 2 days ago BRIEF-BioLine RX presents positive phase 2a AML study and mechanism-of-action data for BL-8040 oncology platform at ASH 2016 Reuters UK, 2 days ago BioLineRx lead product candidate beats cytarabine in myeloid leukemia study Seeking Alpha, 2 days ago
|International Business Times India, 3 days ago|
The PMLA was introduced in 2002 and was amended in 2012 to align with international laws related to AML/CFTDNA, 1 week ago
Karyopharm Presents Updated Phase II SAIL Relapsed/Refractory AML Clinical Data At The American Society of Hematology 2016 Annual Meeting
- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia - NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.BioSpace, 2 days ago Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting SPi World News, 3 days ago Verastem Presents Phase 2 DYNAMO Clinical Data At American Society of Hematology 2016 Annual Meeting BioSpace, 1 day ago Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting Minyanville, 1 day ago
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell..
CRANBURY, N.J. CPI-613 is Cornerstone Pharmaceuticals' lead Altered Energy Metabolism Directed (AEMD) drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting ...ADVFN UK, 1 day ago
on your WebpageAdd Widget >Get your members hooked!